Table 2.
Summary of tick-borne encephalitis vaccines approved for use in the United States, Europe, and Russia. When available, references that evaluate T cell responses are given. Adult doses only are given. Notes: Encepur (GSK) was divested at the end of 2019. FSME-IMMUN was approved to be marketed in the United States under the name TICOVAC in 2021.
| Subtype(s) | Vaccine Name | Manufacturer | Vaccine Type | Target Antigen(s) |
Schedule | Route/Dose | T Cell Response |
|---|---|---|---|---|---|---|---|
| Neudoerf (TBEV-Eu) | FSME-IMMUN/ TICOVAC |
Pfizer | Inactivated whole virus | Whole virus | 3 doses with boosting optional after 3 years | i.m., 2.4 µg | Y- [155] |
| Sofjin (TBEV-FE) | TBEV-Moscow | Chumakov FSC R&D IBP RAS | Inactivated whole virus | Whole virus | Prime/boost | i.m., 1.0 ± 0.5 μg/mL | N |
| Sofjin (TBEV-FE) | Evervac (Phase I/II) |
Chumakov FSC R&D IBP RAS | Inactivated whole virus | Whole virus | Prime/boost | i.m., 0.75 ± 0.15 μg |
N |
| Sofjin (TBEV-FE) | Tick-E-Vac | Chumakov FSC R&D IBP RAS | Inactivated whole virus | Whole virus | Prime/boost | i.m. 0.45 ± 0.05 μg | Y- [163] |
| 205 (TBEV-FE) | EnceVir | Microgen | Inactivated whole virus | Whole virus | Prime/boost | i.m., 2.0–2.5 μg | N |
| Sen-Zhang (TBEV-FE) | SenTaiBao | Changchun Institute of Biol. Products | Inactivated whole virus | Whole virus | Prime/boost | Unknown | N |